ImmuPharma (GB:IMM) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ImmuPharma PLC, a biopharmaceutical company focusing on peptide-based therapeutics, has announced its Annual General Meeting (AGM) to be held on June 28, 2024. Shareholders are informed that the AGM details and Annual Report for 2023 are available on the company’s website. The company specializes in developing treatments for autoimmune diseases, with its leading program, P140, showing promise for Lupus and other autoimmune disorders.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.